Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer New
June 11 2020 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International Reports QuadraMune
Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast
Cancer
New
Patent Filing Suggests Novel Mechanism of Immune Boosting
Nutraceutical Can Augment Efficacy of Cancer
Immunotherapy
OCEANSIDE, CA -- June
11, 2020 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today novel
data suggesting that QuadraMune™ administration reduces
the
number
and activity of immune inhibitory cells termed "myeloid suppressor
cells."
In a series of animal
studies using the triple-negative breast cancer 4T1 mouse model,
the Company showed that administration of QuadraMune™ reduced lung
metastasis on its own and increased efficacy of a "cancer
vaccine". These data suggest that the nutraceutical, which is
currently being tested as a preventative immune booster to protect
against COVID-19 [1],
may have potential use in oncology.
"The patent
that we
previously
filed with the Company possessed data showing that QuadraMune™
suppresses inflammatory molecules which act to deteriorate
antiviral immunity. Some of these molecules, we believe,
activate myeloid suppressor cells" said Dr. James
Veltmeyer, Chief Medical Officer of the Company,
co-inventor
of the patent, and voted Top Doctor of San Diego in
2012,
2014, 2016, 2017, and 2019. "In the current
patent, we cover the use of QuadraMune™ to reduce these immune
inhibitory cells, called Myeloid Suppressor cells, which act as
cancer's shield against the immune response."
The 2018 Nobel Prize
in Medicine was awarded for the discovery of "checkpoint
inhibitors" which are antibodies that suppress immune-suppressive
molecule [2].
Based on the current data, QuadraMune™ appears to work through a
similar mechanism.
"Myeloid Suppressor
Cells, originally described by Dr. Sharwan
Singhal
as "Natural Suppressor" cells, have been shown to correlate with
faster cancer death and treatment unresponsiveness,"
said
Timothy
Dixon, President, and CEO of the Company. "We are excited to
be, to our knowledge, the only company that has developed a
natural-based approach to these "cancer-helping" enemies of the
immune system.
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com and for additional
info on QuadraMune™
visit www.areyoucovidmune.com/covidmune/.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
[1] https://www.clinicaltrials.gov/ct2/show/NCT04421391
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303476/
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
- Company Files New Patent Application on
QuadraMune™ for Reducing Myeloid Suppressor
Cells
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Oct 2023 to Oct 2024